表紙
市場調查報告書

抗病毒藥物市場分析:各作用機制(核苷酸聚合酵素抑制劑,逆轉錄酵素抑制劑,蛋白分解酵素抑制劑),各用途(HIV,肝炎,HSV,流感),各類型(學名藥,品牌藥),市場區隔預測

Antiviral Drugs Market Analysis By Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitor, Protease Inhibitor), By Application (HIV, Hepatitis, HSV, Influenza), By Type (Generic, Branded), & Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 478636
出版日期 內容資訊 英文 85 Pages
商品交期: 2-3個工作天內
價格
Back to Top
抗病毒藥物市場分析:各作用機制(核苷酸聚合酵素抑制劑,逆轉錄酵素抑制劑,蛋白分解酵素抑制劑),各用途(HIV,肝炎,HSV,流感),各類型(學名藥,品牌藥),市場區隔預測 Antiviral Drugs Market Analysis By Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitor, Protease Inhibitor), By Application (HIV, Hepatitis, HSV, Influenza), By Type (Generic, Branded), & Segment Forecasts, 2014 - 2025
出版日期: 2017年02月10日內容資訊: 英文 85 Pages
簡介

本報告提供全球抗病毒藥物市場相關調查,彙整市場趨勢,各作用機制,各用途,各類型,各地區趨勢,打入市場的主要企業簡介等資料。

第1章 調查方法及範圍

第2章 摘要整理

第3章 市場變數,趨勢,範圍

  • 市場區隔和範圍
    • 推動市場的要素分析
    • 阻礙市場的要素分析
    • 嚴厲的法律規章方案
  • 滲透與成長預測製圖
  • SWOT分析
  • 產業分析:波特五力分析

第4章 各作用機制預測與趨勢分析

  • 各作用機制趨勢分析及市場佔有率
  • 核苷酸聚合酵素抑制劑
  • 逆轉錄酵素抑制劑
  • 蛋白分解酵素抑制劑
  • 其他

第5章 各類型預測與趨勢分析

  • 各類型趨勢分析
  • 學名藥
  • 品牌藥

第6章 各用途預測與趨勢分析

  • 各用途趨勢分析
  • HIV
  • 肝炎
  • 皰疹病毒
  • 流感
  • 其他

第7章 各地區預測與趨勢分析

  • 市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第8章 競爭環境

  • 策略架構
  • 市場進入類別
  • 企業簡介
目錄
Product Code: GVR-1-68038-389-8

The global antiviral drugs market is expected to reach a value of USD 69.2 billion by 2025, based on a new report by Grand View Research, Inc. According to the WHO, cases of viral infections increase by more than 1 million each year with around 357 million patients already suffering from one of the four Sexually Transmitted Infections (STIs), such as Acquired Immunodeficiency Syndrome (AIDS).

Introduction of efficient antiviral drugs with benefits such as rapid action, increased sensitivity, and lower adverse effects is expected to serve this market as a high-impact rendering driver over the forecast period. For instance, Gilead Sciences introduced an FDA-approved drug-Genvoya-in 2016 for treatment of AIDS patients who have previously faced adverse effects, such as bone loss and kidney dysfunction.

Low levels of hygiene, growing geriatric population, and increasing awareness through government campaigns are other drivers resulting in high acceptance of antiviral drugs in developing countries.

Further Key Findings From the Study Suggest:

  • Reverse transcriptase inhibitors held the largest share by mechanism of action owing to availability of wide range of product portfolio and presence of new molecules in clinical trials
  • Nucleotide inhibitors are estimated to grow at lucrative rate due to introduction of blockbuster molecules for treatment of Hepatitis C Virus (HCV) infections
  • Generic drugs are anticipated to witness significant CAGR of over 7.0% over the forecast period as result of patent expiry of blockbuster drugs used for treatment of HIV and HCV
  • Branded drugs will hold dominant position in 2025 by drug type due to brand loyalty of healthcare professions despite patent expiration and high price associated with these molecules
  • HIV/AIDS held the dominant share in 2015. High prevalence of HIV infections and presence of favorable government initiatives for curbing them are key factors for high revenue of this segment
  • Hepatitis on the other hand is anticipated to witness flourishing growth over the forecast period owing to introduction of new molecules and approval of novel combination treatments
  • North America was the dominant regional market in 2015. High market share is associated with established R&D infrastructure and growing drug development initiatives
  • Asia Pacific region is anticipated to exhibit fastest regional growth. Local presence of key generic players and growing healthcare infrastructure in this region are key factors for growth
  • Some of the key players of this market include Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline; Bristol-Myers-Squibb; AbbVie; Johnson & Johnson; and Merck & Co. Other generic players in this market are Aurobindo Pharma, Cipla, and Dr Reddy's

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Information Procurement
    • 1.1.1 Purchased database:
    • 1.1.2 GVR's internal database
  • 1.2 Research Methodology
  • 1.3 Geographic scope & assumptions
  • 1.4 Region-wise market calculation
    • 1.4.1 Region-wise market: Base estimates
    • 1.4.2 Global market: CAGR calculation
  • 1.5 Region-based segment share calculation
  • 1.6 List of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Antiviral Drugs Market Variables, Trends & Scope

  • 3.1 Market segmentation& scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Growing geriatric population base
      • 3.1.1.2 Growing prevalence of target diseases
      • 3.1.1.3 Increasing R&D expenditure
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 High cost
    • 3.1.3 Stringent regulatory scenario
  • 3.2 Penetration & growth prospect mapping
  • 3.3 Antiviral Drugs- SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 Antiviral Drugs Market: Mechanism of Action Estimates & Trend Analysis

  • 4.1 Antiviral drugs market: Mechanism of action movement analysis
  • 4.2 Nucleotide polymerase inhibitor
    • 4.2.1 Nucleotide polymerase inhibitor market, 2014 - 2025 (USD Billion)
  • 4.3 Reverse transcriptase inhibitors
    • 4.3.1 Reverse transcriptase inhibitors market, 2014 - 2025 (USD Billion)
  • 4.4 Protease inhibitors
    • 4.4.1 Protease inhibitors market, 2014 - 2025 (USD Billion)
  • 4.5 Others
    • 4.5.1 Others market, 2014 - 2025 (USD Billion)

Chapter 5 Antiviral Drugs Market: Type Estimates & Trend Analysis

  • 5.1 Antiviral drugs market: Type movement analysis
  • 5.2 Generic drugs
    • 5.2.1 Generic drugs market, 2014 - 2025 (USD Billion)
  • 5.3 Branded drugs
    • 5.3.1 Branded drugs market, 2014 - 2025 (USD Billion)

Chapter 6 Antiviral Drugs Market: Application Estimates & Trend Analysis

  • 6.1 Antiviral drugs market: Application movement analysis
  • 6.2 HIV
    • 6.2.1 HIV market, 2014 - 2025 (USD Billion)
  • 6.3 Hepatitis market
    • 6.3.1 Hepatitis market market, 2014 - 2025 (USD Billion)
  • 6.4 Herpes virus
    • 6.4.1 Herpes virus market, 2014 - 2025 (USD Billion)
  • 6.5 Influenza
    • 6.5.1 Influenza market, 2014 - 2025 (USD Billion)
  • 6.6 Others
    • 6.6.1 Others market, 2014 - 2025 (USD Billion)

Chapter 7 Antiviral Drugs Market: Regional Estimates & Trend Analysis, by Application

  • 7.1 Antiviral drugs market share by region, 2015 & 2025
  • 7.2 North America
    • 7.2.1 North America antiviral drugs market, 2014 - 2025 (USD Billion)
    • 7.2.2 U.S
      • 7.2.2.1 U.S antiviral drugs market, 2014 - 2025 (USD Billion)
    • 7.2.3 Canada
      • 7.2.3.1 Canada antiviral drugs market, 2014 - 2025 (USD Billion)
  • 7.3 Europe
    • 7.3.1 Europe antiviral drugs market, 2014 - 2025 (USD Billion)
    • 7.3.2 UK
      • 7.3.2.1 UK antiviral drugs market, 2014 - 2025 (USD Billion)
    • 7.3.3 Germany
      • 7.3.3.1 Germany antiviral drugs market, 2014 - 2025 (USD Billion)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific antiviral drugs market, 2014 - 2025 (USD Billion)
    • 7.4.2 Japan
      • 7.4.2.1 Japan antiviral drugs market, 2014 - 2025 (USD Billion)
    • 7.4.3 China
      • 7.4.3.1 China antiviral drugs market, 2014 - 2025 (USD Billion)
    • 7.4.4 India
      • 7.4.4.1 India antiviral drugs market, 2014 - 2025 (USD Billion)
  • 7.5 Latin America
    • 7.5.1 Latin America antiviral drugs market, 2014 - 2025 (USD Billion)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil antiviral drugs market, 2014 - 2025 (USD Billion)
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico antiviral drugs market, 2014 - 2025 (USD Billion)
  • 7.6 MEA
    • 7.6.1 MEA antiviral drugs market, 2014 - 2025 (USD Billion)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa antiviral drugs market, 2014 - 2025 (USD Billion)

Chapter 8 Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Market Participation Categorization
  • 8.3 Company Profiles
    • 8.3.1 Gilead Sciences
      • 8.3.1.1 Company overview
      • 8.3.1.2 Financial performance
      • 8.3.1.3 Product benchmarking
      • 8.3.1.4 Strategic initiatives
    • 8.3.2 F. Hoffmann-La Roche AG
      • 8.3.2.1 Company overview
      • 8.3.2.2 Financial performance
      • 8.3.2.3 Product benchmarking
      • 8.3.2.4 Strategic initiatives
    • 8.3.3 GlaxoSmithKline
      • 8.3.3.1 Company overview
      • 8.3.3.2 Financial performance
      • 8.3.3.3 Product benchmarking
      • 8.3.3.4 Strategic initiatives
    • 8.3.4 Bristol-Myers-Squibb
      • 8.3.4.1 Company overview
      • 8.3.4.2 Financial performance
      • 8.3.4.3 Product benchmarking
      • 8.3.4.4 Strategic initiatives
    • 8.3.5 AbbVie
      • 8.3.5.1 Company overview
      • 8.3.5.2 Financial performance
      • 8.3.5.3 Product benchmarking
      • 8.3.5.4 Strategic initiatives
    • 8.3.6 Johnson and Johnson
      • 8.3.6.1 Company overview
      • 8.3.6.2 Financial overview
      • 8.3.6.3 Product benchmarking
      • 8.3.6.4 Strategic initiatives
    • 8.3.7 Aurobindo Pharma
      • 8.3.7.1 Company overview
      • 8.3.7.2 Financial overview
      • 8.3.7.3 Product benchmarking
      • 8.3.7.4 Strategic initiatives
    • 8.3.8 Mylan N.V.
      • 8.3.8.1 Company overview
      • 8.3.8.2 Financial overview
      • 8.3.8.3 Product benchmarking
      • 8.3.8.4 Strategic initiatives
    • 8.3.9 Merck & Co
      • 8.3.9.1 Company overview
      • 8.3.9.2 Financial overview
      • 8.3.9.3 Product benchmarking
      • 8.3.9.4 Strategic initiatives
    • 8.3.10 Cipla
      • 8.3.10.1 Company overview
      • 8.3.10.2 Financial overview
      • 8.3.10.3 Product benchmarking
      • 8.3.10.4 Strategic initiatives
    • 8.3.11 Dr. Reddy's Laboratories Ltd
      • 8.3.11.1 Company overview
      • 8.3.11.2 Financial overview
      • 8.3.11.3 Product benchmarking
      • 8.3.11.4 Strategic initiatives

List of Tables

  • TABLE 1: Country share estimation
  • TABLE 2: North America antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 3: North America antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 4: North America antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 5: U.S. antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 6: U.S. antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 7: U.S. antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 8: Canada antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 9: Canada antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 10: Canada antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 11: Europe antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 12: Europe antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 13: Europe antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 14: UK antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 15: UK antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 16: UK antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 17: Germany antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 18: Germany antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 19: Germany antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 20: Asia Pacific antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 21: Asia Pacific antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 22: Asia Pacific antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 23: Japan antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 24: Japan antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 25: Japan antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 26: China antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 27: China antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 28: China antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 29: India antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 30: India antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 31: India antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 32: Latin America antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 33: Latin America antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 34: Latin America antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 35: Brazil antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 36: Brazil antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 37: Brazil antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 38: Mexico antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 39: Mexico antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 40: Mexico antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 41: MEA antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 42: MEA antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 43: MEA antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
  • TABLE 44: South Africa antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
  • TABLE 45: South Africa antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
  • TABLE 46: South Africa antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)

List of Figures

  • FIG. 1: Market research process
  • FIG. 2: Information procurement
  • FIG. 3: Value chain based sizing & forecasting
  • FIG. 4: QFD modeling for market share assessment
  • FIG. 5: Market summary
  • FIG. 6: Market trends &outlook
  • FIG. 7: Market segmentation & scope
  • FIG. 8: Market driver relevance analysis (Current & future impact)
  • FIG. 9: Global percentage of population, by age group, 2050 and 2000
  • FIG. 10: Market restraint relevance analysis (Current & future impact)
  • FIG. 11: Penetration & growth prospect mapping
  • FIG. 12: SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 13: Porter's Five Forces Analysis
  • FIG. 14: Antiviral Drugs market mechanism of action outlook key takeaways
  • FIG. 15: Antiviral drugs market: Mechanism of action movement analysis
  • FIG. 16: Global Nucleotide polymerase inhibitor market, 2014 - 2025 (USD Billion)
  • FIG. 17: Global Reverse transcriptase inhibitors market, 2014 - 2025 (USD Billion)
  • FIG. 18: Global Protease inhibitors market, 2014 - 2025 (USD Billion)
  • FIG. 19: Global vaccines market, 2014 - 2025 (USD Billion)
  • FIG. 20: Antiviral drugs market type outlook key takeaways
  • FIG. 21: antiviral drugs market: Type of Manufacturer movement analysis
  • FIG. 22: Global Generic drugs market, 2014 - 2025 (USD Billion)
  • FIG. 23: Global branded drugs market, 2014 - 2025 (USD Billion)
  • FIG. 24: Antiviral drugs market application outlook key takeaways
  • FIG. 25: Antiviral drugs market: Application movement analysis
  • FIG. 26: Global HIV market, 2014 - 2025 (USD Billion)
  • FIG. 27: Global hepatitis market market, 2014 - 2025 (USD Billion)
  • FIG. 28: Global Herpes virus market, 2014 - 2025 (USD Billion)
  • FIG. 29: Global Influenza market, 2014 - 2025 (USD Billion)
  • FIG. 30: Global Others market, 2014 - 2025 (USD Billion)
  • FIG. 31: Regional market place: Key takeaways
  • FIG. 32: Regional outlook, 2015 & 2024
  • FIG. 33: North America antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 34: U.S. antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 35: Canada antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 36: Europe antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 37: UK antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 38: Germany antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 39: Asia Pacific antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 40: Japan antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 41: China antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 42: India antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 43: Latin America antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 44: Brazil antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 45: Mexico antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 46: MEA antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 47: South Africa antiviral drugs market, 2014 - 2025 (USD Billion)
  • FIG. 48: Strategy framework
  • FIG. 49: Participant categorization
Back to Top